Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease

• Published in: Pharmaceutics Vol. 13; no. 8; p. 1244
• Main Authors: Marquez-Megias, Silvia, Ramon-Lopez, Amelia, Más-Serrano, Patricio, Diaz-Gonzalez, Marcos, Candela-Boix, Maria Remedios, Nalda-Molina, Ricardo
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 12.08.2021; MDPI
• Subjects: adalimumab; Bias; colitis; Crohn's disease; Datasets; Drug dosages; drug monitoring; Immunosuppressive agents; Inflammatory bowel disease; inflammatory bowel diseases; Medical Subject Headings-MeSH; Monoclonal antibodies; Optimization; Patients; Pharmacokinetics; Population; Remission (Medicine); Software; Steroids; Tumor necrosis factor-TNF
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics13081244

Adalimumab is a monoclonal antibody used for inflammatory bowel disease. Due to its considerably variable pharmacokinetics, the loss of response and the development of anti-antibodies, it is highly recommended to use a model-informed precision dosing approach. The aim of this study is to evaluate the predictive performance of different population-pharmacokinetic models of adalimumab for inflammatory bowel disease to determine the pharmacokinetic model(s) that best suit our population to use in the clinical routine. A retrospective observational study with 134 patients was conducted at the General University Hospital of Alicante between 2014 and 2019. Model adequacy of each model was evaluated by the distribution of the individual pharmacokinetic parameters and the NPDE plots whereas predictive performance was assessed by calculating bias and precision. Moreover, stochastic simulations were performed to optimize the maintenance doses in the clinical protocols, to reach the target of 8 mg/L in at least 75% of the population. Two population-pharmacokinetic models were selected out of the six found in the literature which performed better in terms of adequacy and predictive performance. The stochastic simulations suggested the benefits of increasing the maintenance dose in protocol to reach the 8 mg/L target.